AEZS - Aeterna shares rise on potential COVID-19 vaccine exclusive license agreement

Aeterna Zentaris ([[AEZS]] +17.4%) has exercised its option and has entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-19 vaccine currently in preclinical development that was invented at the Julius-Maximilians-University Wuerzburg, one of Germany’s leading research and teaching universities.The company has entered into a research agreement with the university to conduct supplementary research activities and preclinical development studies on the potential vaccine.The vaccine technology developed at the university uses the approved typhoid fever vaccine Salmonella Typhi Ty21a as a carrier strain and has the potential to be an orally active, live-attenuated bacterial vaccine to prevent SARS-CoV-2 infection leading to COVID-19.

For further details see:

Aeterna shares rise on potential COVID-19 vaccine exclusive license agreement